SCHEMBL24966947

SCHEMBL24966947

C=CC(CC)OC(=O)c1cnnn1[C@H](C)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 4/20 0.41
GABRB2 P47870 4/20 0.41
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP11B1 P15538 2/20 0.41
CYP11B2 P19099 2/20 0.41
LMNA P02545 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
ABCB11 O95342 1/20 0.41
GABRA2 P47869 1/20 0.41
BRD4 O60885 6/20 0.38
MAPK1 P28482 1/20 0.37
PTGS2 P35354 2/20 0.37
ALDH1A1 P00352 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CTDSP1 Q9GZU7 1/20 0.33
ALKBH1 Q13686 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24966064 0.83 GABRA1 (0.39) GABRA1GABRB2CYP1A2CYP3A4CYP11B1
SCHEMBL24966998 0.82 BRD4 (0.44) GABRA1GABRB2CYP1A2CYP3A4CYP11B1
SCHEMBL24966744 0.81 CYP1A2 (0.35) GABRA1GABRB2CYP1A2CYP3A4CYP11B1
SCHEMBL24966943 0.81 GABRA1 (0.46) GABRA1GABRB2CYP1A2CYP3A4CYP11B1
SCHEMBL22696925 0.80 GABRA1 (0.66) GABRA1GABRB2CYP1A2CYP3A4CYP11B1
SCHEMBL24966160 0.80 GABRA1 (0.62) GABRA1GABRB2CYP1A2CYP3A4CYP11B1
SCHEMBL23234254 0.79 BRD4 (0.37) GABRA1GABRB2CYP1A2CYP3A4CYP11B1
SCHEMBL24966058 0.78 CYP1A2 (0.35) GABRA1GABRB2CYP1A2CYP3A4CYP11B1
SCHEMBL24966873 0.78 CYP1A2 (0.35) GABRA1GABRB2CYP1A2CYP3A4CYP11B1
SCHEMBL23234121 0.76 ALDH1A1 (0.56) GABRA1GABRB2CYP1A2CYP3A4CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230026724-A1 SUBSTITUTED NITROGEN HETEROCYCLIC COMPOUND AND ANESTHETIC EFFECT THEREOF CHENGDU MFS PHARMA. CO., LTD. (CN) 2023-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230026724-A1 SUBSTITUTED NITROGEN HETEROCYCLIC COMPOUND AND ANESTHETIC EFFECT THEREOF CYP21A2, CYP11B1, CYP11B2 GABRA1 122/4885GABRB2 358/4885CYP1A2 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.